Zydus Lifesciences stock fell 1.40 percent as JV date moved to December 2026

Published on 10/04/2026 at 20:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zydus Lifesciences stock faced a December 2026 JV deadline after its Q1 FY27 profit fell 35.9 percent to INR 9.398 billion. Revenue rose 22 percent.

Zydus Lifesciences, INE010B01027, Illustration mit AI erstellt.

Zydus Lifesciences stock (ISIN INE010B01027) was last at INR 1,145.70 on the NSE on October 1, 2026, down 1.40 percent from the previous close. The immediate company development was a delay to December 2026 for the closing of its 50:50 Sunshine joint venture, formalized in a letter dated October 1, 2026, according to ScanX News.

Sunshine deadline moves to December

The transaction involves Zydus Lifesciences and Sunshine Healthcare Lanka taking equal 50 percent stakes in the joint venture. The revised timetable reflects pending conditions precedent under the shareholders agreement, while the planned investment remains tied to a pharmaceutical manufacturing project in Sri Lanka, ScanX News reported on October 1, 2026.

The delay matters because the partnership is an expansion project rather than a completed operating asset. For shareholders, the December date keeps execution timing ahead of the next major earnings checkpoint and leaves the commercial contribution of the venture dependent on closing.

Revenue growth meets profit pressure

Zydus Lifesciences reported Q1 FY27 operational revenue of INR 80.17 billion, up 22 percent year over year, while consolidated net profit declined 35.9 percent to INR 9.398 billion. EBITDA fell 7.6 percent to INR 19.294 billion, and the EBITDA margin narrowed to 24.1 percent from 31.8 percent in Q1 FY26, according to CNBC TV18.

The figures show the central tension in the stock story: sales expanded by 22 percent, but profit and margin moved in the opposite direction. North American formulations sales were INR 30.98 billion in the quarter, down 2.6 percent year over year but up 4.9 percent sequentially, adding a second measure of the companys uneven regional performance, CNBC TV18 reported.

Targets sit above the NSE price

Business Standard reported on October 2, 2026, that Nirmal Bang Research maintained a Hold rating with a target of INR 1,274, while another brokerage maintained Accumulate with a target of INR 1,200. The report also cited FY26 revenue of INR 271.50 billion and a forecast of INR 334.80 billion for FY28, implying 11 percent annual growth, Business Standard reported.

Investing.com lists a Neutral consensus from 30 analysts, with an average 12-month target of INR 1,197.45, a high estimate of INR 1,457.48 and a low estimate of INR 800. The average target is 4.52 percent above the October 1 price, according to Investing.com.

Zydus Lifesciences stock remains below its yearly high

Zydus Lifesciences stock was last at INR 1,145.70 on the NSE on October 1, 2026, with a 52-week range of INR 835.50 to INR 1,232.10. Its market capitalization was INR 1,142.8 billion and volume was 2,547,369 shares, placing the price 7.02 percent below the 52-week high.